Sicart Associates’s CG Oncology CGON Stock Holding History

Sicart Associates’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Hold	25,000	–	–	0.43%	41
2026 Q1	$1.69M	Hold	25,000	–	–	0.43%	42
2025 Q4	$1.04M	Hold	25,000	–	–	0.28%	45
2025 Q3	$1.01M	Hold	25,000	–	–	0.27%	45
2025 Q2	$650K	Hold	25,000	–	–	0.23%	45
2025 Q1	$612K	Hold	25,000	–	–	0.21%	46
2024 Q4	$717K	Hold	25,000	–	–	0.26%	46
2024 Q3	$943K	Hold	25,000	–	–	0.33%	45
2024 Q2	$789K	Hold	25,000	–	–	0.3%	46
2024 Q1	$1.1M	Buy	+25,000	New	+$1.02M	0.4%	46

Other funds holding CGON

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sicart Associates's CGON Position: Q2 2026 in Review

Sicart Associates held its CG Oncology (CGON) position steady in Q2 2026 at 25,000 shares worth $1.78M. The position accounts for 0.43% of the portfolio, ranked #41.

Sicart Associates first reported a position in CGON in Q1 2024 and has held it in 10 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

Sicart Associates held 25,000 shares of CG Oncology worth $1.78M as of Q2 2026.
Sicart Associates left its CG Oncology share count unchanged in Q2 2026.
CG Oncology made up 0.43% of Sicart Associates's portfolio in Q2 2026, its #41 holding.
Sicart Associates first reported a position in CG Oncology in Q1 2024 and has held it in 10 quarters since.
227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Sicart Associates's 13F filing for Q2 2026, filed 11 Aug 2026.